Engineered T cells may be harnessed to kill solid tumor cells
A new study finds that a form of immunotherapy used to treat the blood cancer leukemia may be effective in treating other kinds of cancer as well.
Read moreCancer
Decades-long drop in breast cancer death rate continues
A decades-long decline in the breast cancer death rate continues, but has begun to slow in recent years.
Read moreDiscovery of new source of cancer antigens may expand cancer vaccine capabilities
Scientists have found a common, new source of tumor mutations that could offer three levels of therapy with a cancer vaccine: 1) a broadly protective, or pan-cancer vaccine 2) cancer-type specific vaccines (e.g. breast vs. pancreatic), 3) personalized cancer vaccines based on mutations unique to an individual.
Read moreImmune therapy eliminates tumor cells in early triple negative breast cancer
Immune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to new results from the KEYNOTE-522 trial. Interim results from the study, which is the first phase III trial of immunotherapy in early breast cancer, also indicated an improvement in event-free survival.
Read moreFirst prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial. This marks a significant advance for prostate cancer treatment, which has lagged behind other common cancers with regard to precision therapy, now the standard of care in breast, ovarian and lung cancers.
Read moreBreast cancer: New data on cohort with recurrence score 26-100 shows 93% cancer-free rate at 5 years
In the prospective TAILORx trial, 93% of women with hormone-sensitive, HER2-negative, axillary node-negative breast cancer and a high Recurrence Score 26-100 were estimated to be cancer-free at five years. This outcome was much better than expected with endocrine therapy alone. The finding adds to limited data on outcomes with a high RS of 26-100, treated with taxane and/or anthracycline-containing chemotherapy plus endocrine therapy. It adds to the body of evidence supporting use of the RS.
Read moreDelivery system can make RNA vaccines more powerful
MIT chemical engineers have developed a new type of lipid nanoparticle that can be used to deliver RNA vaccines. The particles also trigger the release of powerful immune signaling proteins that boost the vaccines' effectiveness.
Read moreWhole genome sequencing could enable personalized cancer treatment
Whole genome sequencing of tumour cells could help predict the prognosis of a patient's cancer and offer clues to identify the most effective treatment, suggests an international study.
Read moreA new mechanism has been revealed which could lead to premature aging in mother cells
A new mechanism makes it possible to understand premature ageing in cells with asymmetrical cell division, as is the case with mother cells. Understanding this mechanism is useful for studying and, in the future, anticipating the development of ageing-related diseases, such as cancer and neurodegenerative processes.
Read moreBuilding a brighter way for capturing cancer during surgery
Bioengineer's smart surgical microscope shows promise for more accurately and quickly identifying cancer cells in the operating room.
Read more